Asia-Pacific Dermatology Drugs Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Jul 2020
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 361
  • No of Figures: 49

Asia-Pacific Dermatology Drugs Market By Drug Class (Corticosteroids, Retinoids, Monoclonal Antibodies, Antibiotics Agent, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs, Others), Drug Type (Branded, Generics), Indication (Infectious Skin Disease, Inflammatory/Autoimmune Disorders, Pigmentation Disorders, Skin Cancer, Others), Prescription Mode (Prescription Based Drugs, Over-The-Counter Drugs), Route of Administration (Oral, Topical, Parenteral), End User (Homecare Healthcare, Hospitals, Dermatology Clinics, Others), Distribution Channel (Retail Pharmacy, Hospitals Pharmacy, Online Pharmacy, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) Industry Trends & Forecast to 2027

Asia-Pacific Dermatology Drugs MarketMarket Analysis and Insights : Asia-Pacific Dermatology Drugs Market

Asia-Pacific dermatology drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 10.5% in the forecast period of 2020 to 2027 and is expected to reach USD 8,068.74 million by 2027 from USD 3,742.88 million in 2019. Increasing prevalence of skin diseases, rising spending on healthcare are the major drivers which propelled the demand of the market in the forecast period.

Dermatology is a medical field that deals with the diagnosis, prevention, and treatment of various skin, nail, and hair-related diseases such as pigmentation, acne, wrinkles, and psoriasis. Dermatological agents, also referred to as dermatologic, are products that are applied topically to the skin. Such drugs are used for the diagnosis of skin diseases and are often used to avoid certain skin disorders. In fact, dermatological are used to protect one's skin for daily skin care. Dermatology drugs are classified into corticosteroids, antifungal drugs, immunosuppressive drugs, monoclonal antibodies, retinoids, antibiotics agent, antiviral agents, and antihistamines agents among others. Dermatology drugs can be administered orally, topically and parenteral. Dermatology drugs can cause various side-effects including neuropsychiatric disorders, facial nerve palsy, headache, dizziness, lethargy, weakness, transient sensory, motor peripheral neuropathies, demyelinating, and autoimmune disorders among others.

Dermatology drug demand has increased as compared to the precise year with growing awareness for diagnostics and treatment of skin diseases. In addition demand of dermatology drug has increased in the developing countries with the increased spending on healthcare. Further product recall of products having these drugs is expected to restraint the usage of dermatology drugs and is expected to slow down the growth of the dermatology drugs market in the forecasted period.

The dermatology drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Dermatology Drugs MarketAsia-Pacific Dermatology Drugs Market Scope and Market Size

Dermatology drugs market is categorized into seven notable segments which are based on the basis of drug class, drug type, prescription mode, indication, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drug class, the market is segmented into corticosteroids, retinoids, monoclonal antibodies, antibiotics agents, antiviral agents, antifungal drugs, antihistamines agents, immunosuppressive drugs and others. In 2020, corticosteroids segment is expected to dominate the market due to the first line treatment for various skin diseases. High volume of corticosteroids sold in the Asia-Pacific region.
  • On the basis of drug type, the market is segmented into branded and generics. In 2020, branded segment is expected to dominate the market due to the account of high penetration as a prescription drug in dermatological therapeutics segment.
  • On the basis of indication, the market is segmented into infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer and others. In 2020, infectious skin disease segment dominates the Asia-Pacific dermatology drugs market, due to large patient pool for skin related disease in Asia-Pacific region which creates high demand for dermatology drugs.
  • On the basis of prescription mode, the market is segmented into prescription based drugs and over-the-counter drugs. In 2020, prescription based drugs segment dominates the Asia-Pacific dermatology drugs market, because maximum branded drugs sold via prescription based drugs mode over others in Asia-Pacific.
  •  On the basis of route of administration, the market is segmented into oral, topical and parenteral. In 2020, topical segment dominates the Asia-Pacific dermatology drugs market; due to majority of dermatology drugs are available in cream, gels, ointment and others.
  • On the basis of end user, the market is segmented into homecare, hospitals, dermatology clinics and others. In 2020, homecare segment dominate the Asia-Pacific dermatology drugs market, due to high volume demand from the end use. Majority of acne and psoriasis drugs sold in the market by end user.
  • On the basis of distribution channel, the market is segmented into retail pharmacy, hospitals pharmacy, online pharmacy and others. In 2020, retail pharmacy segment dominates the Asia-Pacific dermatology drugs market, due to well established retail distribution channel and cost effectiveness of this distribution channel.

Asia-Pacific Dermatology Drugs MarketAsia-Pacific Dermatology Drugs Market Country Level Analysis

Dermatology drugs market is categorized into seven notable segments which are based on the basis of drug class, drug type, prescription mode, and indication, route of administration, end user and distribution channel as referenced above.

The countries covered in Asia-Pacific dermatology drugs market report are the Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific.

In Asia-Pacific, Japan is dominating the market due to increasing focus on the dermatological health and growing awareness about good health and rising spending on healthcare. Whereas China is dominating due to rising spending on health care in the country as demand for branded drugs is increasing, while India is dominating due to the growing awareness for diagnostics and treatment of skin diseases along with the increasing prevalence of skin diseases in the country has boost the demand for dermatology drugs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Partnership and New Product Launch in Asia-Pacific Dermatology Drugs Market is Creating New Opportunities for Players

Dermatology drugs market also provides you with detailed market analysis for every country growth in particular industry with dermatology drug sales, impact of advancement in the dermatology drugs market and changes in regulatory scenarios with their support for the dermatology drugs market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Asia-Pacific Dermatology Drugs Market Share Analysis

Dermatology drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to dermatology drugs market.

The major players covered in the report are Novartis AG, Pfizer Inc., Eli Lilly and Company., Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, Mayne Pharma Group Limited, AbbVie Inc., Cipla Inc, Vibcare Pharma Pvt. Ltd, and Ciaga among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the dermatology drugs market.

For instance,

  • In January 2020, Eli Lilly and Company announced that they have acquired Dermira, which is a biopharmaceutical company engaged in the introduction of novel therapies to treat the chronic skin conditions in a much better way. After this acquisition, the company will expand the pipeline of Lilly's immunology with the addition of lebrikizumab which is a new monoclonal antibody designed to treat atopic dermatitis. This acquisition also expands the company portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium).

Customization Available: Asia-Pacific Dermatology Drugs Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 PREVALENCE OF PSORIASIS IN CHINA

TABLE 2 HEALTH CARE SPENDING IN JAPAN FROM 2005-2016

TABLE 3 APPLICATION AND APPROVAL PROCEDURES AND TIMELINE FOR IMPORTED DRUGS

TABLE 4 TIME TAKEN FOR THE CLINICAL TRIALS

TABLE 5 PRICES OF DRUGS DERMATOLOGY DRUGS IN USD

TABLE 6 BIOLOGICS COMPLETED STUDIES FOR PSORIASIS TREATMENT

TABLE 7 DERMATOLOGY DRUGS SIDE EFFECTS

TABLE 8 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 9 ASIA-PACIFIC CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 10 ASIA-PACIFIC RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 11 ASIA-PACIFIC MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 14 ASIA-PACIFIC ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 15 ASIA-PACIFIC SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 16 ASIA-PACIFIC IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 17 ASIA-PACIFIC ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 18 ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 2018-2027 (USD MILLION)

TABLE 19 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 22 ASIA-PACIFIC INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION 2018-2027 (USD MILLION)

TABLE 23 ASIA-PACIFIC BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 24 ASIA-PACIFIC VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 25 ASIA-PACIFIC FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 27 ASIA-PACIFIC PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 31 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 32 ASIA-PACIFIC TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 33 ASIA-PACIFIC SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 34 ASIA-PACIFIC LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 ASIA-PACIFIC SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC PARENTAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 40 ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 41 JAPAN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 42 JAPAN CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 43 JAPAN ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 44 JAPAN IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 45 JAPAN SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 46 JAPAN IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 47 JAPAN MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 48 JAPAN RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 49 JAPAN ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 50 JAPAN ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 51 JAPAN ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 52 JAPAN DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 53 JAPAN DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 54 JAPAN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 55 JAPAN INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 56 JAPAN BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 57 JAPAN VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 58 JAPAN FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 JAPAN INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 60 JAPAN PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 61 JAPAN HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 62 JAPAN HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 63 JAPAN SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 64 JAPAN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 JAPAN TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 66 JAPAN SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 67 JAPAN LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 68 JAPAN SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 69 JAPAN ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 70 JAPAN PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 71 JAPAN DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 72 JAPAN DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 73 CHINA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 74 CHINA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 75 CHINA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 76 CHINA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 77 CHINA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 78 CHINA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 79 CHINA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 80 CHINA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 81 CHINA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 82 CHINA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 83 CHINA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 84 CHINA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 85 CHINA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 86 CHINA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 87 CHINA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 88 CHINA BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 CHINA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 90 CHINA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 91 CHINA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 92 CHINA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 93 CHINA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 94 CHINA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 95 CHINA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 96 CHINA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 97 CHINA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 98 CHINA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 99 CHINA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 100 CHINA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 101 CHINA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 102 CHINA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 103 CHINA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 104 CHINA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 105 INDIA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 106 INDIA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 107 INDIA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 108 INDIA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 109 INDIA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 110 INDIA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 111 INDIA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 112 INDIA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 113 INDIA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 114 INDIA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 115 INDIA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 116 INDIA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 117 INDIA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 118 INDIA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 119 INDIA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 120 INDIA BACTERIAL IN INFECTIOUS SKIN DISEASE IN DERMATOLOGY MARK ET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 121 INDIA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 122 INDIA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 123 INDIA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 124 INDIA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 125 INDIA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 126 INDIA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 127 INDIA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 128 INDIA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 129 INDIA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 130 INDIA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 131 INDIA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 132 INDIA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 133 INDIA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 134 INDIA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 INDIA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 136 INDIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 137 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 138 AUSTRALIA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 139 AUSTRALIA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 140 AUSTRALIA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 141 AUSTRALIA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 142 AUSTRALIA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 143 AUSTRALIA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 144 AUSTRALIA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 145 AUSTRALIA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 146 AUSTRALIA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 147 AUSTRALIA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 148 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 149 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 150 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 151 AUSTRALIA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 152 AUSTRALIA BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 153 AUSTRALIA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 154 AUSTRALIA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 155 AUSTRALIA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 156 AUSTRALIA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 157 AUSTRALIA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 158 AUSTRALIA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 159 AUSTRALIA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 160 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 161 AUSTRALIA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 162 AUSTRALIA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 163 AUSTRALIA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 164 AUSTRALIA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 AUSTRALIA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 166 AUSTRALIA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 167 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 168 AUSTRALIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 169 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 170 SOUTH KOREA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 171 SOUTH KOREA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 172 SOUTH KOREA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 173 SOUTH KOREA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 174 SOUTH KOREA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 175 SOUTH KOREA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 176 SOUTH KOREA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 177 SOUTH KOREA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 178 SOUTH KOREA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 179 SOUTH KOREA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 180 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 181 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 182 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 183 SOUTH KOREA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 184 SOUTH KOREA BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 185 SOUTH KOREA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 186 SOUTH KOREA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 187 SOUTH KOREA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 188 SOUTH KOREA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 189 SOUTH KOREA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 190 SOUTH KOREA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 191 SOUTH KOREA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 192 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 193 SOUTH KOREA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 194 SOUTH KOREA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 195 SOUTH KOREA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 196 SOUTH KOREA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 197 SOUTH KOREA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 198 SOUTH KOREA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 199 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 200 SOUTH KOREA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 201 MALAYSIA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 202 MALAYSIA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 203 MALAYSIA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 204 MALAYSIA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 205 MALAYSIA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 206 MALAYSIA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 207 MALAYSIA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 208 MALAYSIA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 209 MALAYSIA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 210 MALAYSIA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 211 MALAYSIA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 212 MALAYSIA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 213 MALAYSIA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 214 MALAYSIA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 215 MALAYSIA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 216 MALAYSIA BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 217 MALAYSIA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 218 MALAYSIA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 219 MALAYSIA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 220 MALAYSIA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 221 MALAYSIA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 222 MALAYSIA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 223 MALAYSIA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 224 MALAYSIA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 225 MALAYSIA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 226 MALAYSIA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 227 MALAYSIA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 228 MALAYSIA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 229 MALAYSIA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 230 MALAYSIA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 231 MALAYSIA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 232 MALAYSIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 233 SINGAPORE DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 234 SINGAPORE CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 235 SINGAPORE ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 236 SINGAPORE IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 237 SINGAPORE SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 238 SINGAPORE IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 239 SINGAPORE MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 240 SINGAPORE RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 241 SINGAPORE ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 242 SINGAPORE ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 243 SINGAPORE ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 244 SINGAPORE DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 245 SINGAPORE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 246 SINGAPORE DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 247 SINGAPORE INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 248 SINGAPORE BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 249 SINGAPORE VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 250 SINGAPORE FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 251 SINGAPORE INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 252 SINGAPORE PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 253 SINGAPORE HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 254 SINGAPORE HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 255 SINGAPORE SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 256 SINGAPORE DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 257 SINGAPORE TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 258 SINGAPORE SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 259 SINGAPORE LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 260 SINGAPORE SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 261 SINGAPORE ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 262 SINGAPORE PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 263 SINGAPORE DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 264 SINGAPORE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 265 INDONESIA DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 266 INDONESIA CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 267 INDONESIA ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 268 INDONESIA IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 269 INDONESIA SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 270 INDONESIA IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 271 INDONESIA MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 272 INDONESIA RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 273 INDONESIA ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 274 INDONESIA ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 275 INDONESIA ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 276 INDONESIA DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 277 INDONESIA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 278 INDONESIA DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 279 INDONESIA INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 280 INDONESIA BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 281 INDONESIA VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 282 INDONESIA FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 283 INDONESIA INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 284 INDONESIA PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 285 INDONESIA HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 286 INDONESIA HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 287 INDONESIA SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 288 INDONESIA DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 289 INDONESIA TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 290 INDONESIA SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 291 INDONESIA LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 292 INDONESIA SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 293 INDONESIA ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 294 INDONESIA PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 295 INDONESIA DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 296 INDONESIA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 297 THAILAND DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 298 THAILAND CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 299 THAILAND ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 300 THAILAND IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 301 THAILAND SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 302 THAILAND IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 303 THAILAND MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 304 THAILAND RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 305 THAILAND ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 306 THAILAND ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 307 THAILAND ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 308 THAILAND DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 309 THAILAND DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 310 THAILAND DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 311 THAILAND INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 312 THAILAND BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 313 THAILAND VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 314 THAILAND FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 315 THAILAND INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 316 THAILAND PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 317 THAILAND HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 318 THAILAND HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 319 THAILAND SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 320 THAILAND DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 321 THAILAND TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 322 THAILAND SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 323 THAILAND LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 324 THAILAND SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 325 THAILAND ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 326 THAILAND PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 327 THAILAND DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 328 THAILAND DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 329 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 330 PHILIPPINES CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 331 PHILIPPINES ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 332 PHILIPPINES IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 333 PHILIPPINES SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 334 PHILIPPINES IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 335 PHILIPPINES MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 336 PHILIPPINES RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 337 PHILIPPINES ANTIBIOTICS AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 338 PHILIPPINES ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 339 PHILIPPINES ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

TABLE 340 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 2018-2027 (USD MILLION)

TABLE 341 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION)

TABLE 342 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 343 PHILIPPINES INFECTIOUS SKIN DISEASE IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 344 PHILIPPINES BACTERIAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 345 PHILIPPINES VIRAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 346 PHILIPPINES FUNGAL IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 347 PHILIPPINES INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 348 PHILIPPINES PIGMENTATION DISORDERS IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 349 PHILIPPINES HYPERPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 350 PHILIPPINES HYPOPIGMENTATION IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 351 PHILIPPINES SKIN CANCER IN DERMATOLOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 352 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 353 PHILIPPINES TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 354 PHILIPPINES SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 355 PHILIPPINES LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 356 PHILIPPINES SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 357 PHILIPPINES ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 358 PHILIPPINES PARENTERAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 359 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 360 PHILIPPINES DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 361 REST OF ASIA-PACIFIC DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19